Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Hugh J. McMillan's publication output changed over time?
ScholarIQpublication output · 2016–2022
Output grew300% over the shown period — from 1 works in 2016 to 4 in 2022.
1
2
1
2
2
4
201620172019202020212022
What are the most-cited papers on Hugh J. McMillan?
ScholarIQmost cited works
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Parsons, Perry B. Shieh, Sarah Kavanagh, Sitra Tauscher‐Wisniewski, Bryan E. McGill, Thomas A. Macek
Nature Medicine. 2022304 CitationsOPEN ACCESS
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Deepa H. Chand, F. Mohr, Hugh J. McMillan, F Tukov, Kyle H. Montgomery, A. de Kleyn, Rui Sun, Sitra Tauscher‐Wisniewski, Petra Kaufmann, Gerd A. Kullak‐Ublick
Journal of Hepatology. 2020303 CitationsOPEN ACCESS
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
Erik Landfeldt, Rachel Thompson, Thomas Sejersen, Hugh J. McMillan, Janbernd Kirschner, Hanns Lochmüller
European Journal of Epidemiology. 2020288 CitationsOPEN ACCESS
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Kevin A. Strauss, Michelle A. Farrar, Francesco Muntoni, Kayoko Saito, Jerry R. Mendell, Laurent Servais, Hugh J. McMillan, Richard S. Finkel, Kathryn J. Swoboda, Jennifer M. Kwon, Craig M. Zaidman, Claudia A. Chiriboga, Susan T. Iannaccone, Jena M. Krueger, Julie Parsons, Perry B. Shieh, Sarah Kavanagh, Melissa Wigderson, Sitra Tauscher‐Wisniewski, Bryan E. McGill, Thomas A. Macek
Nature Medicine. 2022282 CitationsOPEN ACCESS
Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
Craig Campbell, Hugh J. McMillan, Jean K. Mah, Mark A. Tarnopolsky, Kathryn Selby, Ty McClure, Dawn Wilson, Matthew L. Sherman, Diana M. Escolar, Kenneth M. Attie
Muscle & Nerve. 2016235 Citations
Related on ScholarIQ
University of Ottawa
Institution
Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial
Paper
Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy
Paper
Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis
Paper
Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the Phase III SPR1NT trial
Paper
Myostatin inhibitor ACE‐031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo‐controlled clinical trial
Paper